Downmodulation of peripheral MOG-specific immunity by pVAXhsp65 treatment during EAE does not reach the CNS

J Neuroimmunol. 2014 Mar 15;268(1-2):35-42. doi: 10.1016/j.jneuroim.2013.12.015. Epub 2014 Jan 6.

Abstract

Most of the therapeutic strategies to control multiple sclerosis are directed to immune modulation and inflammation control. As heat shock proteins are able to induce immunoregulatory T cells, we investigated the therapeutic effect of a genetic vaccine containing the mycobacterial hsp65 gene on experimental autoimmune encephalomyelitis (EAE). Although pVAXhsp65 was immunogenic for mice with EAE and downmodulated specific cytokine induction by MOG, therapy was not able to decrease clinical severity nor to modify immunologic parameters in the CNS. These results indicate that hsp65, administered as a DNA vaccine, was not therapeutic for EAE.

Keywords: CD4+CD25+Foxp3+ T cells; DNA vaccine; Experimental autoimmune encephalomyelitis; hsp65.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cytokines / biosynthesis
  • Cytokines / immunology
  • Encephalomyelitis, Autoimmune, Experimental / immunology*
  • Encephalomyelitis, Autoimmune, Experimental / pathology*
  • Encephalomyelitis, Autoimmune, Experimental / prevention & control
  • Female
  • Heat-Shock Proteins / immunology*
  • Mice
  • Mice, Inbred C57BL
  • Myelin-Oligodendrocyte Glycoprotein / immunology
  • Vaccines, DNA / immunology
  • Vaccines, DNA / pharmacology*

Substances

  • Cytokines
  • Heat-Shock Proteins
  • Mog protein, mouse
  • Myelin-Oligodendrocyte Glycoprotein
  • Vaccines, DNA
  • heat shock protein-65, mouse